Related references
Note: Only part of the references are listed.Molecular characterization of mutant TP53 acute myeloid leukemia and high-risk myelodysplastic syndrome
Tim Grob et al.
BLOOD (2022)
TP53 mutation defines a unique subgroup within complex karyotype de novo and therapy-related MDS/AML
Olga K. Weinberg et al.
BLOOD ADVANCES (2022)
High-resolution structural variant profiling of myelodysplastic syndromes by optical genome mapping uncovers cryptic aberrations of prognostic and therapeutic significance
Hui Yang et al.
LEUKEMIA (2022)
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms
Joseph D. Khoury et al.
LEUKEMIA (2022)
Diagnosis and Treatment of Myelodysplastic Syndromes A Review
Mikkael A. Sekeres et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2022)
Treatment of myelodysplastic syndromes in the era of precision medicine and immunomodulatory drugs: a focus on higher-risk disease
Razan Mohty et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2022)
Therapy-related myelodysplastic syndromes deserve specific diagnostic sub-classification and risk-stratification-an approach to classification of patients with t-MDS
A. Kuendgen et al.
LEUKEMIA (2021)
Enasidenib (ENA) Is Effective in Patients with IDH2 Mutated Myelodysplastic Syndrome (MDS) : The Ideal Phase 2 Study By the GFM Group
Lionel Ades et al.
BLOOD (2021)
Ivosidenib Monotherapy Is Effective in Patients with IDH1 Mutated Myelodysplastic Syndrome (MDS): The Idiome Phase 2 Study By the GFM Group
Marie Sebert et al.
BLOOD (2021)
Personalized Prediction Model to Risk Stratify Patients With Myelodysplastic Syndromes
Aziz Nazha et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Classification and Personalized Prognostic Assessment on the Basis of Clinical and Genomic Features in Myelodysplastic Syndromes
Matteo Bersanelli et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome
Ryotaro Nakamura et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
Current challenges and unmet medical needs in myelodysplastic syndromes
Uwe Platzbecker et al.
LEUKEMIA (2021)
Peri-transfusion quality-of-life assessment for patients with myelodysplastic syndromes
Gregory A. Abel et al.
TRANSFUSION (2021)
Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes
Pierre Fenaux et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
SF3B1-mutant MDS as a distinct disease subtype: a proposal from the International Working Group for the Prognosis of MDS
Luca Malcovati et al.
BLOOD (2020)
Genetics of progression from MDS to secondary leukemia
Andrew J. Menssen et al.
BLOOD (2020)
Myelodysplastic syndromes: 2021 update on diagnosis, risk stratification and management
Guillermo Garcia-Manero et al.
AMERICAN JOURNAL OF HEMATOLOGY (2020)
Implications ofTP53allelic state for genome stability, clinical presentation and outcomes in myelodysplastic syndromes
Elsa Bernard et al.
NATURE MEDICINE (2020)
Myelodysplastic Syndromes
Mario Cazzola
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it
Amer M. Zeidan et al.
BLOOD REVIEWS (2019)
TP53 mutation status divides myelodysplastic syndromes with complex karyotypes into distinct prognostic subgroups
Detlef Haase et al.
LEUKEMIA (2019)
Integrating patient-centered factors in the risk assessment of MDS
Rena J. Buckstein
Hematology-American Society of Hematology Education Program (2019)
Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
Hsin-An Hou et al.
BLOOD CANCER JOURNAL (2018)
Prognosis of patients with intermediate risk IPSS-R myelodysplastic syndrome indicates variable outcomes and need for models beyond IPSS-R
Christopher B. Benton et al.
AMERICAN JOURNAL OF HEMATOLOGY (2018)
Frailty and the management of hematologic malignancies
Gregory A. Abel et al.
BLOOD (2018)
Patient-Reported Outcomes Enhance the Survival Prediction of Traditional Disease Risk Classifications: An International Study in Patients With Myelodysplastic Syndromes
Fabio Efficace et al.
CANCER (2018)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Clinical Implications of Genetic Mutations in Myelodysplastic Syndrome
James A. Kennedy et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Adding molecular data to prognostic models can improve predictive power in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2017)
Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System
M. G. Della Porta et al.
LEUKEMIA (2017)
Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation
R. C. Lindsley et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Molecular analysis of myelodysplastic syndrome with isolated deletion of the long arm of chromosome 5 reveals a specific spectrum of molecular mutations with prognostic impact: a study on 123 patients and 27 genes
Manja Meggendorfer et al.
HAEMATOLOGICA (2017)
Validation of the revised IPSS at transplant in patients with myelodysplastic syndrome/transformed acute myelogenous leukemia receiving allogeneic stem cell transplantation: a retrospective analysis of the EBMT chronic malignancies working party
C. Scheid et al.
BONE MARROW TRANSPLANTATION (2017)
Clinical significance of somatic mutation in unexplained blood cytopenia
Luca Malcovati et al.
BLOOD (2017)
Genetic abnormalities in myelodysplasia and secondary acute myeloid leukemia: impact on outcome of stem cell transplantation
Tetsuichi Yoshizato et al.
BLOOD (2017)
Time-dependent changes in mortality and transformation risk in MDS
Michael Pfeilstoecker et al.
BLOOD (2016)
The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia
Daniel A. Arber et al.
BLOOD (2016)
Patient-related factors independently impact overall survival in patients with myelodysplastic syndromes: an MDS-CAN prospective study
Rena Buckstein et al.
BRITISH JOURNAL OF HAEMATOLOGY (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
Incorporation of molecular data into the Revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
A. Nazha et al.
LEUKEMIA (2016)
Prospective international validation of the Quality of Life in Myelodysplasia Scale (QUALMS)
Gregory A. Abel et al.
HAEMATOLOGICA (2016)
MDS prognostic scoring systems - Past, present, and future
Brian A. Jonas et al.
BEST PRACTICE & RESEARCH CLINICAL HAEMATOLOGY (2015)
Impact of comorbidities by ACE-27 in the revised-IPSS for patients with myelodysplastic syndromes
Naval Daver et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Landscape of genetic lesions in 944 patients with myelodysplastic syndromes
T. Haferlach et al.
LEUKEMIA (2014)
Validation of the revised International Prognostic Scoring System in treated patients with myelodysplastic syndromes
Asmita Mishra et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Molecular Pathophysiology of Myelodysplastic Syndromes
R. Coleman Lindsley et al.
ANNUAL REVIEW OF PATHOLOGY: MECHANISMS OF DISEASE, VOL 8 (2013)
The genetic basis of myelodysplasia and its clinical relevance
Mario Cazzola et al.
BLOOD (2013)
Clinical and biological implications of driver mutations in myelodysplastic syndromes
Elli Papaemmanuil et al.
BLOOD (2013)
Recent advances in understanding the molecular pathogenesis of myelodysplastic syndromes
Austin G. Kulasekararaj et al.
BRITISH JOURNAL OF HAEMATOLOGY (2013)
Prognostic Factors and Risk Models in Myelodysplastic Syndromes
Rami S. Komrokji et al.
Clinical Lymphoma Myeloma & Leukemia (2013)
Single Nucleotide Polymorphism Array Karyotyping: A Diagnostic and Prognostic Tool in Myelodysplastic Syndromes with Unsuccessful Conventional Cytogenetic Testing
Leonor Arenillas et al.
GENES CHROMOSOMES & CANCER (2013)
There's Risk, and Then There's RISK: The Latest Clinical Prognostic Risk Stratification Models in Myelodysplastic Syndromes
Amer M. Zeidan et al.
CURRENT HEMATOLOGIC MALIGNANCY REPORTS (2013)
Epidemiology of Myelodysplastic Syndromes
Xiaomei Ma
AMERICAN JOURNAL OF MEDICINE (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Validation of the MD Anderson Prognostic Risk Model for patients with myelodysplastic syndrome
Rami S. Komrokji et al.
CANCER (2012)
Validation of a Prognostic Model and the Impact of Mutations in Patients With Lower-Risk Myelodysplastic Syndromes
Rafael Bejar et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
The genetic basis of phenotypic heterogeneity in myelodysplastic syndromes
Azra Raza et al.
NATURE REVIEWS CANCER (2012)
Risk stratification based on both disease status and extra-hematologic comorbidities in patients with myelodysplastic syndrome
Matteo G. Della Porta et al.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL (2011)
Use of Whole-Genome Sequencing to Diagnose a Cryptic Fusion Oncogene
John S. Welch et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2011)
TP53 Mutations in Low-Risk Myelodysplastic Syndromes With del(5q) Predict Disease Progression
Martin Jaedersten et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Somatic SF3B1 Mutation in Myelodysplasia with Ring Sideroblasts
E. Papaemmanuil et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Clinical Effect of Point Mutations in Myelodysplastic Syndromes
Rafael Bejar et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System
Hagop Kantarjian et al.
CANCER (2008)
A prognostic score for patients with lower risk myelodysplastic syndrome
G. Garcia-Manero et al.
LEUKEMIA (2008)
Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML
Lukasz P. Gondek et al.
BLOOD (2008)
Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes
Luca Malcovati et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Myelodysplastic syndromes - Incidence and survival in the United States
Xiaomei Ma et al.
CANCER (2007)
Share Paper
